Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

AxoGen

Phunware Inc

Western Digital

Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).

4 Must-Buy Stocks for Remarkable Earnings Acceleration

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?

Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice

Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade

Protagonist Therapeutics (PTGX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why

Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published in the New England Journal of Medicine reporting results from the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE study of rusfertide Our Partner, Johnson & Johnson Innovative Medicine (formerly Janssen) initiated an expanded JNJ-2113 clinical development program with four Phase 3 studies in moderate-to-severe psoriasis and one Phase 2b study in moderately-to-severely active ulcerative colitis Protagonist achieved $60 million in milestones in Q4 related to JNJ-2113 NEWARK, CA / ACCESSWIRE / February 27, 2024 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "The fourth quarter of 2023 was an extremely busy and productive time for Protagonist," said Dinesh V.

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form - REVIVE is one of two pivotal studies, including an ongoing Phase 3 study, VERIFY, which is nearing enrollment completion NEWARK, CA / ACCESSWIRE / February 21, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced publication in the New England Journal of Medicine (NEJM) of the REVIVE Phase 2 study (NCT04057040) results evaluating the efficacy and safety of rusfertide in polycythemia vera (PV), a myeloproliferative neoplasm affecting approximately 160,000 patients in the United States (US). Rusfertide, a peptide mimetic of the natural hormone hepcidin, represents a novel erythrocytosis-specific approach for the potential treatment of PV.

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hired Vice President and Controller, in accordance with the terms of Mr. Reddy's employment offer letter.

Protagonist Therapeutics Reports Granting of Inducement Awards

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial evaluating JNJ-2113 in adults living with moderate-to-severe plaque psoriasis (PsO).

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Takeda Pharmaceutical

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV) Takeda Will Make an Upfront Payment of $300 Million at Closing Partnership Combines Protagonist's Leadership in Pharmaceutical Peptide Drug Development With Takeda's Commercial Expertise and 70-Plus Year Legacy of Driving Innovation Within the Rare Hematology Community Protagonist to Host Conference Call and Webcast Today at 4:30 PM ET OSAKA, JAPAN, CAMBRIDGE, MA, and NEWARK, CA / ACCESSWIRE / January 31, 2024 / Takeda ( TSE:4502/NYSE:TAK ) and Protagonist Therapeutics, Inc., ( Nasdaq:PTGX ) today announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV). PV is a rare chronic blood disorder characterized by excessive production of red blood cells that affects as many as 160,000 patients in the U.S.[i], with a similar prevalence in Europe[ii][iii].

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the Company has now earned $60 million in payments in the fourth quarter of 2023 for milestones achieved in the JNJ-2113 Phase 2b and Phase 3 clinical programs led by the Company's collaboration partner, Janssen Biotech, Inc., a Johnson & Johnson company ("Johnson & Johnson").

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics is developing two parallel programs in different disease areas and has recovered in market valuation. The company will present important data on hematocrit control and iron deficiency in patients with polycythemia vera at the ASH meeting. PTGX is also developing JNJ-2113, an IL-23 receptor blocker, for autoimmune diseases, and has commenced clinical studies for plaque psoriasis and ulcerative colitis.

Protagonist Therapeutics: On A Ship That Could Be About To Sail

Johnson & Johnson

CVRx

Legend Biotech

J&J's biggest position is in a biotech that's developing cancer cell therapies. The healthcare giant's second-largest stake is in a medical device maker that focuses on heart failure.

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

NEWARK, CA / ACCESSWIRE / November 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) today announced it ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. Life sciences and software companies dominated at the top of the Fast 500 this year; Protagonist joins Vir Biotechnology and Moderna among the top companies across all sectors.

Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)

The consensus price target hints at a 141.1% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?

Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023) Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral IL-23 receptor antagonist peptide drug candidate for moderate-to-severe plaque psoriasis presented in July 2023 JNJ-2113 clinical development program advances with two Phase 3 studies in moderate-to-severe psoriasis and a Phase 2b study in moderately-to-severely active ulcerative colitis (UC) commencing in Q4 2023; additional Phase 3 studies in psoriasis expected to begin in Q1 2024 Forecast cash runway through Q1 2026[1] NEWARK, CA / ACCESSWIRE / November 2, 2023 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. "In the third quarter of 2023, Protagonist continued to make rapid progress with its key programs," said Dinesh V.

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the treatment of Polycythemia Vera and other disease indications NEWARK, CA / ACCESSWIRE / November 2, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that five abstracts relevant to the Company's rusfertide program have been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH), taking place December 9-12, 2023 in San Diego, California. "We are extremely pleased to present a broad cross-section of new data at ASH this year," said Dinesh V.

Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting

NEWARK, CA / ACCESSWIRE / October 30, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors.

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

ICONIC Phase 3 clinical program initiation in adults with moderate to severe plaque psoriasis ANTHEM Phase 2b initiation in ulcerative colitis Company is eligible to receive next two milestone payments for a total of $60M NEWARK, CA / ACCESSWIRE / October 9, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that the company will be eligible to receive $60M in milestone payments in the fourth quarter for the advancement of JNJ-2113 into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Company's partner in the development of JNJ-2113. The ICONIC clinical development program in adult patients with moderate to severe psoriasis (PsO) is advancing to Phase 3 with two studies starting in November, and the ANTHEM-UC Phase 2b study in adults with moderately to severely active ulcerative colitis (UC) will begin this month.

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

NEWARK, CA / ACCESSWIRE / October 3, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on September 29, 2023, it issued inducement awards to Katharina Modelska, M.D., Ph.D., the Company's recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. Modelska's employment offer letter.

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only oral IL-23 targeting molecule in development, but if it fails, it will join other abandoned Johnson & Johnson projects. Johnson & Johnson plans to proceed with a phase 3 trial for JNJ-2113 despite Tremfya's stronger numerical data, citing ease of administration and potential benefits for some patients.

News for Protagonist Therapeutics Stock (PTGX)